Sukhmani Padda, MD, discusses how third-generation tyrosine kinase inhibitors compare to the first- and second-generation TKIs.
Sukhmani Padda, MD, assistant professor of medicine at Stanford University, discusses how third-generation EGFR tyrosine kinase inhibitors (TKIs) compare to the first- and second-generation TKIs.
Osimertinib (Tagrisso) is currently the only approved third-generation TKI, but this agent has dramatically changed the treatment landscape in lung cancer, says Padda.
Unlike earlier generation TKIs, the third-generation TKIs select for activity againstT709M
Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions
March 26th 2024According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Read More